Trials / Unknown
UnknownNCT03521219
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
Single Arm, Exploratory and Open Clinical Trial of Second-line Therapy With Apatinib Mesylate in Advanced Cholangiocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2018-02-07
- Primary completion
- 2018-11-01
- Completion
- 2019-11-01
- First posted
- 2018-05-11
- Last updated
- 2018-05-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03521219. Inclusion in this directory is not an endorsement.